89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the […]